首页> 外文OA文献 >Medical management of primary hyperparathyroidism: Proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism
【2h】

Medical management of primary hyperparathyroidism: Proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism

机译:原发性甲状旁腺功能亢进症的医疗管理:第四届无症状原发性甲状旁腺功能亢进管理国际研讨会论文集

摘要

OBJECTIVE:ududAsymptomatic primary hyperparathyroidism (PHPT) is a common clinical problem. The only available definitive therapy is parathyroidectomy, which is appropriate to consider in all patients. The purpose of this report is to provide an update on calcium and vitamin D supplementation and medical management for those patients with PHPT who cannot or do not want to undergo surgery.udMETHODS:ududQuestions were developed by the International Task Force on PHPT. A comprehensive literature search was undertaken, and relevant articles published between 2008 and 2013 were reviewed in detail. The questions were addressed by the panel of experts, and consensus was established at the time of the workshop.udCONCLUSIONS:ududThe recommended calcium intake in patients with PHPT should follow guidelines established for all individuals. It is not recommended to limit calcium intake in patients with PHPT who do not undergo surgery. Patients with low serum 25-hydroxyvitamin D should be repleted with doses of vitamin D aiming to bring serum 25-hydroxyvitamin D levels to ≥ 50 nmol/L (20 ng/mL) at a minimum, but a goal of ≥75 nmol/L (30 ng/mL) also is reasonable. Pharmacological approaches are available and should be reserved for those patients in whom it is desirable to lower the serum calcium, increase BMD, or both. For the control of hypercalcemia, cinacalcet is the treatment of choice. Cinacalcet reduces serum calcium concentrations to normal in many cases, but has only a modest effect on serum PTH levels. However, bone mineral density (BMD) does not change. To improve BMD, bisphosphonate therapy is recommended. The best evidence is for the use of alendronate, which improves BMD at the lumbar spine without altering the serum calcium concentration. To reduce the serum calcium and improve BMD, combination therapy with both agents is reasonable, but strong evidence for the efficacy of that approach is lacking.
机译:目的: ud ud无症状原发性甲状旁腺功能亢进症(PHPT)是常见的临床问题。唯一可用的确定性疗法是甲状旁腺切除术,适合所有患者考虑。本报告的目的是为那些无法或不想进行手术的PHPT患者提供有关钙和维生素D补充和医疗管理的最新信息。 udMETHODS: ud ud问题由PHPT国际工作组制定。进行了全面的文献检索,并详细审查了2008年至2013年之间发表的相关文章。问题由专家小组解决,并在研讨会期间达成共识。 ud结论: ud udPHPT患者的建议钙摄入量应遵循为所有个体制定的指南。不建议不进行手术的PHPT患者限制钙的摄入。血清25-羟基维生素D低的患者应补充维生素D,以使血清25-羟基维生素D的水平最低达到≥50 nmol / L(20 ng / mL),但目标是≥75 nmol / L (30 ng / mL)也很合理。药理学方法是可用的,应保留给希望降低血清钙,增加BMD或两者兼而有之的患者。对于控制高钙血症,西那卡塞是首选治疗方法。在许多情况下,西那卡塞可将血清钙浓度降低至正常水平,但对血清PTH水平影响不大。但是,骨矿物质密度(BMD)不变。为了改善BMD,建议使用双膦酸盐治疗。最好的证据是使用了阿仑膦酸盐,它可以改善腰椎的骨密度,而不会改变血清钙的浓度。为了降低血清钙含量和改善BMD,两种药物联合治疗是合理的,但是尚缺乏强有力的证据证明该方法的有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号